Sarcoma News

Eribulin mesylate significantly improved survival compared with dacarbazine among patients with advanced intermediate or high-grade liposarcoma or leiomyosarcoma who failed first- and second-line treatments, according to randomized, phase 3 study results published in The Lancet.

In 1971, President Nixon signed the National Cancer Act declaring a war against cancer, which transformed our ability to diagnose, treat and reduce morbidity and mortality from cancer.

The turmoil of December and early January has died down, and I have had time to think about the upcoming year, which seems to offer the possibility of being a year that could present some substantial hazards.

Unprovoked venous thromboembolism appeared associated with a consistently high risk for subsequent cancer diagnosis, according to results of a population-based cohort study.

The FDA granted orphan drug status to tazemetostat for the treatment of malignant rhabdoid tumors, according to a press release from the agent’s manufacturer.

Jaclyn Biegel, PhD, has been named director of the Center for Personalized Medicine at Children’s Hospital Los Angeles.

Immigrants are considerably underserved in terms of health care in the United States.

The FDA granted orphan drug designation to TRC105 for the treatment of patients with soft tissue sarcoma.

Pediatric oncology and bioethics experts have issued a framework for the allocation of scarce drugs to reduce waste and prioritize treatment across and within diseases, according to a commentary published in Journal of the National Cancer Institute.

The FDA today approved the chemotherapy drug eribulin mesylate for the treatment of patients with unresectable or metastatic liposarcoma who previously received anthracycline-containing chemotherapy.